期刊文献+

解毒化瘀汤治疗真性红细胞增多症临床效果观察

Clinical Effect of Jiedu Huayu Decoction on Polycythemia Vera
下载PDF
导出
摘要 目的:观察真性红细胞增多症患者采用解毒化瘀汤治疗的临床价值及可行性。方法:将2017年2月至2018年2月期间我院收治的真性红细胞增多症患者70例纳入研究,35例实施解毒化瘀汤联合羟基脲治疗者为观察组,35例实施羟基脲治疗者为对照组,比较两组患者治疗前后血液学指标变化情况,临床治疗效果以及主症证候积分。结果:治疗后,观察组患者各项血液学指标(RBC、Hb)较比对照组更具优越性(P<0.05);观察组患者的总有效率(94.29%)明显高于对照组(74.29%),P<0.05;治疗后,观察组患者的刺痛、皮下瘀斑及脉络淤血等症状评分均优于对照组(P<0.05)。结论:解毒化瘀汤治疗真性红细胞增多症的临床疗效确切,安全性高,对加速患者康复具有指导意义。 Objective:To observe the clinical value and feasibility of dispersing blood stasis and detoxifying decoction decoction in the treatment of polycythemia vera.Method:Select 70 polycythemia patients who were treated in our hospital from Feb.2017 to Feb.2018.Take 35 patients who were treated by dispersing blood stasis and detoxifying decoction combine with hydroxycarbamide as observation group,while take the other 35 patient who were treated by hydroxycarbamide as control group.Then contract the changes of blood index,clinical treatment effect,and the score of cardinal syndrome between the two groups before and after treatment.Results:After treatment,RBC and Hb in the observation group were superior to those in the control group(P<0.05);the total effective rate in the observation group(94.29%)was significantly higher than that in the control group(74.29%),P<0.05;after treatment,the symptom scores of tingling,subcutaneous ecchymosis and choroidal congestion in the observation group were better than those in the control group(P<0.05).Conclusion:Jiedu Huayu decoction is effective and safe in the treatment of polycythemia vera,which has guiding significance in accelerating the rehabilitation of patients.
作者 蒋占平 JIANG Zhan-ping(Department of Hematology,First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China)
出处 《药品评价》 CAS 2019年第17期31-32,共2页 Drug Evaluation
关键词 真性红细胞增多症 解毒化瘀汤 羟基脲 血液学 Polycythemia Vera Dispersing Blood Stasis and Detoxifying Decoction Hydroxycarbamide Hematology
  • 相关文献

参考文献5

二级参考文献45

  • 1陈治水,危北海,张万岱,李道本.溃疡性结肠炎中西医结合诊治方案(草案)[J].中国中西医结合消化杂志,2005,13(2):133-136. 被引量:182
  • 2欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495. 被引量:751
  • 3Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical Concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi:10.1200/JCO. 2010.31.8436.
  • 4Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [J]. N Engl J Med, 2007, 356(5) :459-468. doi: 10.1056/NEJMoa065202.
  • 5Bench A J, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations [ J ]. Br J Haematol, 2013, 160(1):25-34. doi: 10.1111/bjh.12075.
  • 6Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification [J]. Am J Hematol, 2014, 89(2):199-202. doi: 10.1002/ajh.23617.
  • 7Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnos- tic criteria of polycythemia vera [J]. Leukemia, 2014, 28 (6): 1191-1195. doi: 10.1038/leu.2013.380.
  • 8Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post- polycythemia vera and post- essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment [J]. Leukemia, 2008, 22(2):437-438. doi:10.1038/sj. leu.2404914.
  • 9Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an intemational study[J]. Leukemia, 2013, 27(9):1874-1881. doi: 10.1038/1eu.2013.163.
  • 10Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera [J]. N Engl J Med, 2013, 368( 1 ):22-33. doi: 10.1056/NEJMoa1208500.

共引文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部